Background: At the start of the coronavirus disease 2019 (COVID-19) pandemic, many
national health organizations emphasized nonpharmacologic interventions, such as quarantining
or physical distancing. In the United Kingdom, strict self-isolation (“shielding”)
was advised for those deemed to be clinically extremely vulnerable on the basis of
the presence of selected medical conditions or at the discretion of their general
practitioners.
Down syndrome features on neither the U.K. shielding list nor the U.S. Centers for
Disease Control and Prevention list of groups at “increased risk.” However, it is
associated with immune dysfunction, congenital heart disease, and pulmonary pathology
and, given its prevalence, may be a relevant albeit unconfirmed risk factor for severe
COVID-19 (1).
Objective: To evaluate Down syndrome as a risk factor for death from COVID-19 through
a comprehensive analysis of individual-level data in a cohort study of 8.26 million
adults (aged >19 years), as part of a wider COVID-19 risk prediction project commissioned
by the U.K. government (2).
Methods and Findings: We used QResearch, a population-level primary care database
that has collected data for more than 35 million persons in England since 1998 and
is linked at the individual patient level to severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) testing results from Public Health England, hospital episode statistics,
and the Office of National Statistics death registry. Data extracted included age,
sex, ethnicity, alcohol intake, smoking status, body mass index (BMI), a range of
preexisting comorbid conditions, and concurrent medications. The primary outcome of
interest was COVID-19 mortality in or out of the hospital, defined as confirmed or
suspected COVID-19 on the death certificate or death within 28 days of a confirmed
SARS-CoV-2 infection in the study period. The secondary outcome of interest was hospital
admission related to COVID-19. The study period was 24 January 2020 (first confirmed
SARS-CoV-2 infection in the United Kingdom) to 30 June 2020. We used Cox proportional
hazards models to estimate adjusted hazard ratios (HRs) with 95% CIs, accounting for
death from non–COVID-19 causes as a competing event by censoring all persons who did
not have the outcome of interest at the study end date. We tested for interactions
between Down syndrome and age, BMI, and sex.
The Table shows selected demographic and clinical characteristics for the cohort.
Of 8.26 million adults in the study cohort, 4053 had Down syndrome. Sixty-eight persons
with Down syndrome died, 27 (39.7%) of COVID-19, 17 (25.0%) of pneumonia or pneumonitis,
and 24 (35.3%) of other causes. Of the 8 252 105 persons without Down syndrome, 41 685
died, 8457 (20.3%) of COVID-19, 5999 (14.4%) of pneumonia or pneumonitis, and 27 229
(65.3%) of other causes.
Table. Selected Clinical and Demographic Features of the Study Cohort, by Down Syndrome
Status*
Table. Selected Clinical and Demographic Features of the Study Cohort, by Down Syndrome
Status*
Adjusted for age and sex, the HR for COVID-19–related death in adults with versus
without Down syndrome was 24.94 (95% CI, 17.08 to 36.44). After adjustment for age,
sex, ethnicity, BMI, dementia diagnosis, care home residency, congenital heart disease,
and a range of other comorbid conditions and treatments (Table), the HR for COVID-19–related
death was 10.39 (CI, 7.08 to 15.23); for hospitalization, it was 4.94 (CI, 3.63 to
6.73) (Figure). There was no evidence of interactions between Down syndrome and age,
sex, or BMI. The HR for death was not affected by further adjustment for smoking status
and alcohol intake (HR, 10.12 [CI, 6.90 to 14.84]). For those with learning disabilities
other than Down syndrome, the adjusted HR for COVID-19–related death was 1.27 (CI,
1.16 to 1.40).
Figure.
Adjusted HR (95% CI) for the association between Down syndrome and death from COVID-19.
Adjusted for the variables shown, deprivation, fractional polynomial terms for body
mass index (BMI), and age. The model includes fractional polynomial terms for age,
BMI, and interaction terms between age terms and type 2 diabetes. We used the QResearch
database, version 44. The study period was 24 January 2020 to 30 June 2020. CF = cystic
fibrosis; COVID-19 = coronavirus disease 2019; GP = general practitioner; HR = hazard
ratio; LABA = long-acting β2-agonist; MND = motor neurone disease; MS = multiple sclerosis;
SLE = systemic lupus erythematosus.
* HR for type 2 diabetes reported at mean age.
Figure. Adjusted HR (95% CI) for the association between Down syndrome and death from
COVID-19. Adjusted for the variables shown, deprivation, fractional polynomial terms
for body mass index (BMI), and age. The model includes fractional polynomial terms
for age, BMI, and interaction terms between age terms and type 2 diabetes. We used
the QResearch database, version 44. The study period was 24 January 2020 to 30 June
2020. CF = cystic fibrosis; COVID-19 = coronavirus disease 2019; GP = general practitioner;
HR = hazard ratio; LABA = long-acting β2-agonist; MND = motor neurone disease; MS =
multiple sclerosis; SLE = systemic lupus erythematosus. * HR for type 2 diabetes reported
at mean age.
Discussion: We estimated a 4-fold increased risk for COVID-19–related hospitalization
and a 10-fold increased risk for COVID-19–related death in persons with Down syndrome,
a group that is currently not strategically protected. This was after adjustment for
cardiovascular and pulmonary diseases and care home residence, which our results suggest
explained some but not all of the increased risk. These estimated adjusted associations
do not have a direct causal interpretation because some adjusted variables may lie
on causal pathways, but they can inform policy and motivate further investigation.
Participation in day care programs or immunologic deficits could be implicated, for
example. Down syndrome is the most common genetic cause of intellectual disability,
with multiorgan manifestations (3). Predisposition to pneumonias and acute respiratory
distress syndrome in children, airway anomalies, pulmonary hypoplasia, and inhibited
pulmonary angiogenesis have been reported (4, 5).
We are unaware of the effects of Down syndrome on COVID-19 outcomes being reported
elsewhere yet during this pandemic. Novel evidence that specific conditions may confer
elevated risk should be used by public health organizations, policymakers, and health
care workers to strategically protect vulnerable individuals.